Arctic Bioscience AS (OSL:ABS)
Norway · Delayed Price · Currency is NOK 2.800
0.00 (0.00%)
Sep 17, 2026, 9:50 AM CET
Arctic Bioscience AS Income Statement
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 46.17 | 40.1 | 43.48 | 33.75 | 34.27 | 21.52 |
Other Revenue | 2.79 | 2.52 | 0.91 | - | 0.2 | 0 |
| 48.96 | 42.62 | 44.39 | 33.75 | 34.47 | 21.52 | |
Revenue Growth | 6.71% | -4.00% | 31.53% | -2.09% | 60.21% | 4.48% |
Cost of Revenue | 33.93 | 29.05 | 29.26 | 23.98 | 22.63 | 15.72 |
Gross Profit | 15.03 | 13.56 | 15.14 | 9.77 | 11.84 | 5.8 |
Selling, General & Admin | 25.59 | 24.41 | 25.95 | 23.51 | 21.69 | 17.26 |
Other Operating Expenses | 16.3 | 17.48 | 29.5 | 29.47 | 21.15 | 25.96 |
Operating Expenses | 46.67 | 47.01 | 60.6 | 58.37 | 46.57 | 45.74 |
Operating Income | -31.64 | -33.45 | -45.46 | -48.59 | -34.73 | -39.94 |
Interest Expense | -9.45 | -9.09 | -3.15 | -0.99 | -0 | -0.34 |
Interest & Investment Income | 1.54 | 2.06 | 2.05 | 3.74 | 1.89 | 0.12 |
Currency Exchange Gain (Loss) | -0.42 | -0.42 | 0.9 | - | - | - |
Other Non Operating Income (Expenses) | -0.13 | -0.13 | 0.06 | 0.33 | 1.47 | -1.78 |
EBT Excluding Unusual Items | -40.1 | -41.03 | -45.61 | -45.52 | -31.36 | -41.94 |
Gain (Loss) on Sale of Assets | 0.01 | 0.01 | 0.01 | 0.01 | - | - |
Other Unusual Items | - | - | -2.34 | - | -2.66 | -0.64 |
Pretax Income | -40.1 | -41.03 | -47.93 | -45.51 | -34.02 | -42.58 |
Net Income | -40.1 | -41.03 | -47.93 | -45.51 | -34.02 | -42.58 |
Net Income to Common | -40.1 | -41.03 | -47.93 | -45.51 | -34.02 | -42.58 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 27 | 27 | 25 | 25 | 24 | 24 |
Shares Outstanding (Diluted) | 27 | 27 | 25 | 25 | 24 | 24 |
Shares Change | 3.97% | 6.42% | -0.26% | 3.88% | 0.60% | 75.31% |
EPS (Basic) | -1.48 | -1.52 | -1.89 | -1.79 | -1.39 | -1.75 |
EPS (Diluted) | -1.48 | -1.52 | -1.89 | -1.79 | -1.39 | -1.75 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -25.39 | -45.4 | -96.17 | -65.07 | -83.96 | -76 |
Free Cash Flow Per Share | -0.94 | -1.68 | -3.79 | -2.56 | -3.43 | -3.12 |
Gross Margin | 30.70% | 31.83% | 34.10% | 28.96% | 34.36% | 26.95% |
Operating Margin | -64.61% | -78.49% | -102.41% | -143.98% | -100.75% | -185.63% |
Profit Margin | -81.90% | -96.27% | -107.98% | -134.86% | -98.71% | -197.90% |
Free Cash Flow Margin | -51.86% | -106.53% | -216.64% | -192.81% | -243.58% | -353.22% |
EBITDA | -29.98 | -30.59 | -40.31 | -43.21 | -31 | -37.42 |
EBITDA Margin | -61.22% | -71.79% | -90.81% | -128.03% | -89.92% | -173.92% |
D&A For EBITDA | 1.66 | 2.86 | 5.15 | 5.38 | 3.73 | 2.52 |
EBIT | -31.64 | -33.45 | -45.46 | -48.59 | -34.73 | -39.94 |
EBIT Margin | -64.61% | -78.49% | -102.41% | -143.98% | -100.75% | -185.63% |
Revenue as Reported | 48.96 | 42.62 | 44.4 | 33.76 | 34.47 | 21.52 |